Adial Pharmaceuticals: Anticipated CEO & CFO Changes; Annual Meeting Set

What Happened
Adial Pharmaceuticals, Inc. (ADIL) filed an 8-K (Aug 13, 2026) announcing that, if certain proposals receive stockholder approval at the Company’s 2026 Annual Meeting, current President & CEO Cary Claiborne’s employment will be terminated promptly after the meeting and Chief Development Officer and director Matthew Davidson is expected to be appointed President & CEO. The filing also states that CFO Vinay Shah’s employment is expected to be terminated promptly after the meeting if the Stockholder Approval is obtained and that a new CFO will be appointed. Messrs. Claiborne and Shah would be entitled to severance payments and benefits under their amended and restated employment agreements, subject to execution of a release. The Board indicated it anticipates changes to its size and composition following Stockholder Approval but has not made definitive determinations.

Key Details

• CEO: Cary Claiborne anticipated to be terminated and Matthew Davidson expected to be appointed President & CEO, contingent on stockholder approval at the 2026 Annual Meeting.
• CFO: Vinay Shah anticipated to be terminated contingent on the same approval; a new CFO will be appointed.
• Severance: Both Claiborne and Shah would receive severance per their amended and restated employment agreements, conditioned on signing releases.
• Annual Meeting & deadlines: 2026 Annual Meeting set for Thursday, Sept. 17, 2026; deadline to submit Rule 14a-8 stockholder proposals or other timely proposals is Aug. 23, 2026. Proxy materials will be filed later.

Why It Matters
This filing signals a potential leadership transition (CEO and CFO) that is contingent on stockholder votes at the Sept. 17, 2026 annual meeting. Leadership and board changes can affect company strategy, development priorities, and investor perception. The severance obligations—conditioned on releases—are contractual items investors should note when assessing potential near-term corporate expenses. Shareholders who want to submit proposals or nominate directors must meet the revised Aug. 23, 2026 deadline.